Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Undecaprenyl-phosphate N-acetylglucosaminyl 1-phosphate transferase (TagO) is an essential bacterial membrane enzyme that catalyzes the first committed step in the biosynthesis of wall teichoic acids (WTAs) in Gram-positive bacteria. Specifically, it transfers N-acetylglucosamine-1-phosphate (GlcNAc-1-P) from UDP-GlcNAc to the lipid carrier undecaprenyl phosphate (Und-P). WTAs are crucial components of the Gram-positive cell wall, playing key roles in cell division, cell shape maintenance, and virulence. Inhibition or deletion of TagO leads to a lack of WTAs, resulting in morphological defects, increased susceptibility to host immune factors like lysozyme, and impaired biofilm formation. Consequently, TagO is considered an attractive target for the development of novel antibacterial agents, particularly against drug-resistant pathogens like methicillin-resistant Staphylococcus aureus (MRSA). Natural products such as tunicamycin and CPZEN-45 have been shown to target TagO, although off-target inhibition of mammalian glycosylation enzymes presents a significant therapeutic challenge.
Inhibitor
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Undecaprenyl-phosphate N-acetylglucosaminyl 1-phosphate transferase (TagO).